Annika Kim Constantino is a Digital Reporter at CNBC. She covers the biotech and pharmaceutical industry, focusing on themes such as medicine and healthcare, public health, and pharmaceutical regulation. Annika's work has been featured in notable outlets including NBC News, Yahoo News, and NBC Bay Area.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Annika Kim Constantino's coverage primarily focuses on the healthcare and pharmaceutical industry within the United States. She frequently cites data, reports on government announcements, and incorporates press releases into her articles.
Given this focus, she may be receptive to pitches from experts in the healthcare and pharmaceutical industries who can provide analysis or commentary on drug approvals, vaccine development, health regulations, company news (especially those related to U.S.-based companies), patent challenges, or other relevant topics within the realm of healthcare and pharmaceuticals.
Pitches offering insights based on solid data or relating to recent government announcements in the U.S. healthcare sector would likely align well with Annika's coverage preferences.
This information evolves through artificial intelligence and human feedback. Improve this profile .
CVS will add Zepbound coverage on Oct. 1, and start covering Lilly's newly approved Foundayo pill on June 1. The move will boost Lilly's efforts to maintain its dominance over
By: Annika Kim Constantino
Officials are more concerned about highly contagious diseases like measles and respiratory viruses, which can spread quickly through large, fast-moving crowds.
By: Annika Kim Constantino
The U.S. will lean on the same playbook it did starting in the late 1950s, part of which involves releasing sterile insects to suppress the pest's population.
By: Annika Kim
Below are some highlights from the conversation with Katerina Guerraz, Aetna's chief operating officer and president of Medicaid, and Tilak Mandadi, CVS Health's chief experience and technology officer.
Key Points Centene said it offered buyouts to some employees as the health insurer grapples with higher medical costs, funding cuts and membership declines.
By: Annika Kim
Key Points Millions of older Americans in Medicare are about to gain access to obesity drugs through Medicare's new Bridge demonstration program for a monthly copay of just $50.
By: Annika Kim
Key Points Starting Wednesday, eligible seniors with Medicare coverage can access GLP-1s for obesity with a copay of just $50 per month through a temporary program called Bridge.
By: Annika Kim
The huge shift in Medicare policy is going to open up access to millions of older Americans who previously couldn't afford blockbuster GLP-1s from and to treat obesity.
By: Annika Kim
Meanwhile, 60% of employers said they offer coverage for diabetes only, up from 55% in 2025 and 57% in 2024.
By: Annika Kim
Key Points Vivani Medical believes a tiny implant placed under the skin could help address the biggest issue with blockbuster GLP-1s: keeping patients on treatment to maintain their weight loss.
